Director, Program Management at Abata Therapeutics

San Diego, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Immuno-OncologyIndustries

Requirements

Bachelor’s degree in Life Sciences, Biotechnology, Project Management, or a related field. Advanced degree preferred
Minimum of 10 years of program management experience in the biotech or pharmaceutical industry
Proven track record in managing programs from early development through late-stage clinical milestones, including regulatory submissions, within oncology programs
Deep understanding of biotech industry standards, regulatory frameworks, and clinical development processes
Strong leadership presence with the ability to influence across all levels of the organization
Excellent strategic thinking, communication, and interpersonal skills
Proficiency in project management tools and software (MS Project preferred)

Responsibilities

Provide strategic leadership for cross-functional drug development teams, ensuring strict alignment with corporate goals and scientific priorities
Partner with Project Team Leader (PTL) to drive the development and execution of integrated program strategies, including timelines, budgets, risk mitigation plans, and resource allocation
Oversee planning and execution of key drug development milestones (e.g., IND, IP availability, FIP, data readouts, regulatory filings), ensuring cross-functional coordination and accountability
Drive decision-making and issue resolution at the program level, proactively identifying risks and implementing mitigation strategies
Apply deep understanding of oncology drug development practices to assist PTL in identifying and planning for key strategic inflection points and stage gates to de-risk next phase of development and other ongoing programs within the portfolio
Serve as a key liaison between program teams and executive leadership, delivering critical updates, strategic recommendations, and facilitating governance interactions
Anticipate, identify, and resolve program risks, issues, resource gaps and acceleration opportunities
Present critical program updates, strategic recommendations, and respond to questions from senior leadership and governance bodies
Lead continuous improvement initiatives to enhance portfolio planning data integrity, streamline workflows, and optimize vendor and team collaboration
Establish, maintain and enforce best practices in program management, knowledge sharing, and operational excellence
Facilitate transparent communication across department subject matter experts and with external partners to ensure program alignment and momentum
Mentor and guide junior program managers and contribute to the growth of the Program & Portfolio Management function
Represent Janux externally with partners, vendors, and regulatory bodies as needed
Perform other duties as assigned

Skills

Program Management

Oncology Drug Development

Cross-Functional Leadership

Strategic Planning

Risk Mitigation

Timeline Management

Budget Management

Resource Allocation

IND Filings

Regulatory Filings

Clinical Development

Portfolio Management

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free